Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
about
Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyTargeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacyTumor-associated macrophages: unwitting accomplices in breast cancer malignancy.Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.Functionally diverse human T cells recognize non-microbial antigens presented by MR1.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity.Pancreatic cancer: Update on immunotherapies and algenpantucel-L.Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and ImmunotherapiesKick-starting the cancer-immunity cycle by targeting CD40.Immuno-oncology combinations: raising the tail of the survival curve.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution.Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers.Targets for immunotherapy of liver cancer.Targeting the tumour stroma to improve cancer therapy.
P2860
Q28066199-E84D55ED-5777-4FA9-B844-F4B4EE01E3F8Q28354371-AA79E356-E2D3-4BE5-B696-639D8178FF0CQ36692838-F179A029-FA07-42AB-A64A-0AF07EF1C8EEQ37109800-577D2D4E-7F52-47B9-A27A-2391F6B22F3AQ37562562-783935E4-5FE7-48F5-880B-2819919AF7C0Q38778174-9735CBF9-6111-4568-B47B-5C3ACD5ED44AQ38786054-5AF53F2E-FC41-404F-BD89-D50F6593052EQ38910078-F3DDB8DF-A16C-4D9D-A584-83AEC37C66CFQ39096364-09FF0987-DE30-436C-9208-BF9B30B1FCF3Q39268764-36ABD899-021D-4847-BDA4-C560FECEB297Q40176792-FF120BEC-3840-4775-8211-5CA84ED62781Q40261599-442BB8D3-E752-4A6B-85F2-76E15EF6A6D7Q41011622-827D657A-9A05-4DBE-9F19-AF6397017E94Q41590380-A71498E4-BCB6-4548-A99D-3298AE2A876CQ42421273-112157D8-8FE3-420B-90D8-9E1AC5743225Q46047154-D060497B-D114-480E-81AF-84E1823A4A9DQ47325431-2E22539E-3A81-4642-A9AB-FC9DC858FA0DQ47433391-144ADFB5-E6A9-4574-8E3A-F426D39FA055Q47448276-061491A6-E3CE-40FC-9964-1D8E1EC3B743Q47965755-4A51EB66-2F5B-4F3A-8D39-C8F3CDFFCF34Q52322982-DF9D46C0-3F0B-4148-93B2-E47AF8D15EAC
P2860
Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
@en
type
label
Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
@en
prefLabel
Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
@en
P2093
P1476
Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
@en
P2093
Alfred Zippelius
Jens Schreiner
Petra Herzig
Philipp Müller
P304
P356
10.1158/2326-6066.CIR-14-0226
P577
2015-01-26T00:00:00Z